On November 4, 2016, Biocept, Inc. (the
) voluntarily terminated the common stock purchase agreement (the
) that the Company entered into on December 21, 2015, with Aspire Capital Fund, LLC (
).Pursuant to the Purchase Agreement, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $15.0 million of shares of the Companys common stock over the 30-month term of the Purchase Agreement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized .
Dated: November 4, 2016
/s/ Michael W. Nall
Michael W. Nall
President and Chief Executive Officer
makes a similar move, sign up!
Other recent filings from the company include the following:
Biocept director just picked up 5,667 shares - March 29, 2017
Biocept just filed a prospectus, suggesting it plans to soon issue some securities - March 29, 2017
Biocept Just Filed Its Annual Report: 12. Net Loss per Co... - March 28, 2017
Shareholder Director - March 23, 2017
CFO of Biocept was just granted 16,383 options - March 22, 2017